Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Best Practices, LLC Study Examines How Pharmaceutical Industry is Successfully Executing Risk Evaluation and Mitigation Strategies Programs


CHAPEL HILL, N.C., Oct. 18, 2017 /PRNewswire/ -- Developing an effective, yet innovative, Risk Evaluation and Mitigation Strategy (REMS) plan is a delicate balancing act for pharmaceutical companies.

Given the complexity of balancing regulatory requirements and commercial objectives, Best Practices, LLC conducted a study to examine how leading life sciences and medical device companies develop and execute successful REMS plans for newly-approved drugs in the U.S. market. To inform these efforts, Best Practices, LLC published "REMS Excellence: Models & Trends in Supporting REMS Program Success."

Most companies start REMS planning for a new product during Phase III or earlier, and organizations use new technology, certification and similar tools to guarantee compliance by physicians and distributors, according to the study.

In particular, the study provides insights around the structure and responsibilities of REMS teams, use of internal and external resources to support REMS programs, physician/ distributor compliance on ETASU, current challenges in REMS communication plans and innovative REMS approaches for new products.

The study found that most companies have relatively limited experience in implementing a REMS plan. On average, benchmark companies have only deployed REMS plans for 4.7 products since the Food and Drug Administration's Amendments Act of 2007 was issued.

With REMS requirements so infrequent for most drug manufacturers, it is critical to leverage as much internal experience as possible.

Key topics covered in this new report include:

Twenty leaders from 17 leading biopharmaceutical and medical device companies participated in this study.

To learn more about this report, download a complimentary report excerpt at http://www.best-in-class.com/rr1469.htm.

For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

SOURCE Best Practices, LLC


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: